Primary mucinous adenocarcinoma of the female urethra

A contemporary clinicopathologic analysis

Saul E. Harari, Liang Cheng, Adeboye O. Osunkoya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Primary mucinous adenocarcinoma of the female urethra is very rare and may lead to both diagnostic and therapeutic challenges. Although primary mucinous adenocarcinoma of the prostate and prostatic urethra has been well characterized in men, this is the largest clinicopathologic study to date of primary mucinous adenocarcinoma of the female urethra. A search was made through the files of 2 major academic institutions for cases of confirmed primary mucinous adenocarcinoma arising from the female urethra. Tumors arising from adjacent organs were excluded both clinically and pathologically in all cases. Five cases were identified. The mean patient age was 67 years (range, 54-74 years). All patients presented with a polypoid/papillary mass arising from the urethra. Pathologic stages were as follows: pT4 3 (60%) of 5 cases; pT3 1 (20%) of 5 cases, and pT2 1 (20%) of 5 cases. Immunohistochemical stains for GATA3, p63, CK7, CK20, CDX2, ER, PAX8, and β-catenin were performed on all cases. Immunohistochemical stains were positive in the tumor cells for CDX2 in 4/5 (80%) cases; focally positive for CK20 in 4/5 (80%) cases; focally positive for CK7 in 4/5 cases (80%); and negative for p63, GATA3, ER, PAX8 and β-catenin in all cases. In the 4 patients with available follow-up data, mean follow-up was 25 months (range, 4-54 months). It is critical for pathologists to be aware of this entity in light of potential diagnostic pitfalls and therapeutic implications.

Original languageEnglish (US)
Pages (from-to)132-137
Number of pages6
JournalHuman Pathology
Volume47
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Mucinous Adenocarcinoma
Urethra
Catenins
Coloring Agents
Prostate
Neoplasms
Therapeutics

Keywords

  • Clinicopathologic analysis
  • Female urethra
  • Follow-up
  • Immunohistochemistry
  • Mucinous adenocarcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Primary mucinous adenocarcinoma of the female urethra : A contemporary clinicopathologic analysis. / Harari, Saul E.; Cheng, Liang; Osunkoya, Adeboye O.

In: Human Pathology, Vol. 47, No. 1, 01.01.2016, p. 132-137.

Research output: Contribution to journalArticle

@article{a6115e2b3a134f27b00394e9db6e0ca7,
title = "Primary mucinous adenocarcinoma of the female urethra: A contemporary clinicopathologic analysis",
abstract = "Primary mucinous adenocarcinoma of the female urethra is very rare and may lead to both diagnostic and therapeutic challenges. Although primary mucinous adenocarcinoma of the prostate and prostatic urethra has been well characterized in men, this is the largest clinicopathologic study to date of primary mucinous adenocarcinoma of the female urethra. A search was made through the files of 2 major academic institutions for cases of confirmed primary mucinous adenocarcinoma arising from the female urethra. Tumors arising from adjacent organs were excluded both clinically and pathologically in all cases. Five cases were identified. The mean patient age was 67 years (range, 54-74 years). All patients presented with a polypoid/papillary mass arising from the urethra. Pathologic stages were as follows: pT4 3 (60{\%}) of 5 cases; pT3 1 (20{\%}) of 5 cases, and pT2 1 (20{\%}) of 5 cases. Immunohistochemical stains for GATA3, p63, CK7, CK20, CDX2, ER, PAX8, and β-catenin were performed on all cases. Immunohistochemical stains were positive in the tumor cells for CDX2 in 4/5 (80{\%}) cases; focally positive for CK20 in 4/5 (80{\%}) cases; focally positive for CK7 in 4/5 cases (80{\%}); and negative for p63, GATA3, ER, PAX8 and β-catenin in all cases. In the 4 patients with available follow-up data, mean follow-up was 25 months (range, 4-54 months). It is critical for pathologists to be aware of this entity in light of potential diagnostic pitfalls and therapeutic implications.",
keywords = "Clinicopathologic analysis, Female urethra, Follow-up, Immunohistochemistry, Mucinous adenocarcinoma",
author = "Harari, {Saul E.} and Liang Cheng and Osunkoya, {Adeboye O.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.humpath.2015.09.014",
language = "English (US)",
volume = "47",
pages = "132--137",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Primary mucinous adenocarcinoma of the female urethra

T2 - A contemporary clinicopathologic analysis

AU - Harari, Saul E.

AU - Cheng, Liang

AU - Osunkoya, Adeboye O.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Primary mucinous adenocarcinoma of the female urethra is very rare and may lead to both diagnostic and therapeutic challenges. Although primary mucinous adenocarcinoma of the prostate and prostatic urethra has been well characterized in men, this is the largest clinicopathologic study to date of primary mucinous adenocarcinoma of the female urethra. A search was made through the files of 2 major academic institutions for cases of confirmed primary mucinous adenocarcinoma arising from the female urethra. Tumors arising from adjacent organs were excluded both clinically and pathologically in all cases. Five cases were identified. The mean patient age was 67 years (range, 54-74 years). All patients presented with a polypoid/papillary mass arising from the urethra. Pathologic stages were as follows: pT4 3 (60%) of 5 cases; pT3 1 (20%) of 5 cases, and pT2 1 (20%) of 5 cases. Immunohistochemical stains for GATA3, p63, CK7, CK20, CDX2, ER, PAX8, and β-catenin were performed on all cases. Immunohistochemical stains were positive in the tumor cells for CDX2 in 4/5 (80%) cases; focally positive for CK20 in 4/5 (80%) cases; focally positive for CK7 in 4/5 cases (80%); and negative for p63, GATA3, ER, PAX8 and β-catenin in all cases. In the 4 patients with available follow-up data, mean follow-up was 25 months (range, 4-54 months). It is critical for pathologists to be aware of this entity in light of potential diagnostic pitfalls and therapeutic implications.

AB - Primary mucinous adenocarcinoma of the female urethra is very rare and may lead to both diagnostic and therapeutic challenges. Although primary mucinous adenocarcinoma of the prostate and prostatic urethra has been well characterized in men, this is the largest clinicopathologic study to date of primary mucinous adenocarcinoma of the female urethra. A search was made through the files of 2 major academic institutions for cases of confirmed primary mucinous adenocarcinoma arising from the female urethra. Tumors arising from adjacent organs were excluded both clinically and pathologically in all cases. Five cases were identified. The mean patient age was 67 years (range, 54-74 years). All patients presented with a polypoid/papillary mass arising from the urethra. Pathologic stages were as follows: pT4 3 (60%) of 5 cases; pT3 1 (20%) of 5 cases, and pT2 1 (20%) of 5 cases. Immunohistochemical stains for GATA3, p63, CK7, CK20, CDX2, ER, PAX8, and β-catenin were performed on all cases. Immunohistochemical stains were positive in the tumor cells for CDX2 in 4/5 (80%) cases; focally positive for CK20 in 4/5 (80%) cases; focally positive for CK7 in 4/5 cases (80%); and negative for p63, GATA3, ER, PAX8 and β-catenin in all cases. In the 4 patients with available follow-up data, mean follow-up was 25 months (range, 4-54 months). It is critical for pathologists to be aware of this entity in light of potential diagnostic pitfalls and therapeutic implications.

KW - Clinicopathologic analysis

KW - Female urethra

KW - Follow-up

KW - Immunohistochemistry

KW - Mucinous adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84952639406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952639406&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.09.014

DO - 10.1016/j.humpath.2015.09.014

M3 - Article

VL - 47

SP - 132

EP - 137

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -